{
    "clinical_study": {
        "@rank": "82241", 
        "arm_group": {
            "arm_group_label": "Treatment", 
            "arm_group_type": "Experimental", 
            "description": "Endostar d1-d7 15mg/d Oxaliplatin 85 mg/m2 d6 Folinic acid 400 mg/m2 d6 5-FU 400 mg/m2 d6, and then 5-FU 2,400 mg/m2 INTRAVENOUS over 46 h"
        }, 
        "brief_summary": {
            "textblock": "This study is to assess the efficacy and safety of Endostar combined with mFOLFOX6 in\n      untreated metastatic colorectal cancer patients, and to find the markers that may predict\n      the efficacy."
        }, 
        "brief_title": "Endostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancer", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed metastatic colorectal cancer\n             (adenocarcinoma)\n\n          -  At least one measurable lesion (RECIST criteria)\n\n          -  Life expectancy \u2265 3 months\n\n          -  ECOG performance status 0-2\n\n          -  Adequate hematologic function: ANC \u2265 1.5\u00d7109 /L\uff0cHb \u2265 90 g/L\uff0cPLT \u2265 100\u00d7109 /L\n\n          -  Adequate renal function: Cr \u2264 1.25\u00d7ULN or Creatinine clearance \u2265 60 ml/min\n\n          -  Adequate hepatic function: BIL \u2264 1.5\u00d7ULN, ALT/AST \u2264 2.5\u00d7ULN, Alkaline phosphatase \u2264\n             5\u00d7ULN\n\n          -  Patients have not previously received palliative chemotherapy, immunological/\n             biological treatment\n\n          -  No adjuvant chemotherapy in last six months\n\n          -  Target lesion has not received local radiotherapy\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Diagnosis of colorectal neuroendocrine tumor, undifferentiated carcinoma,\n             adenosquamous carcinoma, squamous cell carcinoma\n\n          -  Evidence of serious or uncontrolled infection\n\n          -  Serious cardiovascular disease (congestive heart failure, uncontrollable arrhythmia,\n             unstable angina, myocardial infarction, serious heart valve disease, resistant\n             hypertension)\n\n          -  Pregnant or lactating women\n\n          -  Women of childbearing potential refused to practice acceptable methods of birth\n             control to prevent pregnancy\n\n          -  Allergic to any of the study drug\n\n          -  Intestinal obstruction, intestinal perforation, or stroke within 3 months\n\n          -  Participation in other clinical studies"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01832948", 
            "org_study_id": "20121201E-mCRC"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment", 
                "intervention_name": "Endostar", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment", 
                "intervention_name": "Oxaliplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment", 
                "intervention_name": "Folinic acid", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment", 
                "intervention_name": "5-FU", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Leucovorin", 
                "Folic Acid", 
                "Levoleucovorin", 
                "Oxaliplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 11, 2013", 
        "location": {
            "contact": {
                "last_name": "Liming Zhu, MD", 
                "phone": "0571-88122222"
            }, 
            "facility": {
                "address": {
                    "city": "Hangzhou", 
                    "country": "China", 
                    "state": "Zhejiang"
                }, 
                "name": "Zhejiang Cancer Hospital"
            }, 
            "investigator": {
                "last_name": "Liming Zhu, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Study of Endostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancer and Efficacy Prediction", 
        "overall_contact": {
            "last_name": "Liming Zhu, MD", 
            "phone": "0571-88122222"
        }, 
        "overall_official": {
            "affiliation": "Zhejiang Cancer Hospital", 
            "last_name": "Liming Zhu, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Objective Response Rate (ORR)", 
            "safety_issue": "No", 
            "time_frame": "the end of the 3rd cycle"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01832948"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Blood perfusion in tumor tissue", 
                "safety_issue": "No", 
                "time_frame": "baseline, the end of the 3rd cycle"
            }, 
            {
                "measure": "Ratio of blood perfusion in tumor tissue to blood perfusion in surrounding normal tissue", 
                "safety_issue": "No", 
                "time_frame": "baseline, the end of the 3rd cycle"
            }, 
            {
                "measure": "Incidence of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 1 month after the last cycle"
            }
        ], 
        "source": "Zhejiang Cancer Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zhejiang Cancer Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}